U-VUE Biomarker Datasheet - BIM
|Alternative Name:||Bcl-2-like protein 11|
|Main cell types:|
|Subcellular Location:||Nuclear and cytoplasmic; staining is present on the membrane of the nucleus and mitochondria|
BIM is a pro-apoptotic member of the Bcl-2 family of proteins. Expression of this protein can be induced by nerve growth factor (NGF) and forkhead transcription factor suggesting that this protein plays a role in neuronal and lymphocyte apoptosis.
IHC: Anti-BIM antibody [Y36] staining normal tonsil FFPE tissue (brown). Hematoxylin counterstain in blue.
IHC: Anti-BIM antibody conjugate [Y36] staining normal tonsil FFPE tissue (brown). Hematoxylin counterstain in blue.
ISP: Anti-BIM antibody conjugate [Y36] staining normal tonsil FFPE tissue (green). Nuclear counterstain in blue.
- Karachaliou, Niki et al. “BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.” Scientific reports vol. 5 17499. 7 Dec. 2015, DOI: 10.1038/srep17499
- Sakuma, Yuji et al. “WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.” Laboratory investigation; a journal of technical methods and pathology vol. 92,3 (2012): 371-83. DOI: 10.1038/labinvest.2011.187
- Huang, Hongbiao et al. “Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.” Oncotarget vol. 7,3 (2016): 2796-808. DOI: 10.18632/oncotarget.6425
Each lot of antibody conjugate reagent is quality control tested on positive control tissue and reviewed by Ultivue’s Pathology and Biomarker Analytics group to ensure appropriate staining patterns and signal intensity.
This U-VUE Antibody Conjugate is for Research Use Only. Not for Diagnostic purposes.